Amgen Inc. (AMGN): Price and Financial Metrics
AMGN Stock Summary
- Amgen Inc's market capitalization of $149,462,628,593 is ahead of 98.54% of US-listed equities.
- AMGN's went public 35.33 years ago, making it older than 92.8% of listed US stocks we're tracking.
- The volatility of Amgen Inc's share price is greater than that of only 1.87% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to Amgen Inc, a group of peers worth examining would be AZN, TXN, BA, SNY, and LLY.
- Visit AMGN's SEC page to see the company's official filings. To visit the company's web site, go to www.amgen.com.
AMGN Stock Price Chart Interactive Chart >
AMGN Price/Volume Stats
|Current price||$255.31||52-week high||$276.69|
|Prev. close||$258.78||52-week low||$210.28|
|Day high||$258.48||Avg. volume||2,624,665|
|50-day MA||$241.02||Dividend yield||2.72%|
|200-day MA||$239.63||Market Cap||147.01B|
Amgen Inc. (AMGN) Company Bio
Amgen discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company was founded in 1980 and is based in Thousand Oaks, California.
AMGN Price Forecast Based on DCF Valuation
|Current Price||DCF Fair Value Target:||Forecasted Gain:|
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Amgen Inc. To summarize, we found that Amgen Inc ranked in the 39th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Amgen Inc ended up being:
- The compound growth rate in the free cash flow of Amgen Inc over the past 5.52 years is 0.02%; that's higher than merely 24.54% of free cash flow generating stocks in the Healthcare sector.
- Amgen Inc's weighted average cost of capital (WACC) is 9%; for context, that number is higher than only 18.22% of tickers in our DCF set.
|Terminal Growth Rate in Free Cash Flow||Return Relative to Current Share Price|
AMGN Latest News Stream
|Loading, please wait...|
AMGN Latest Social Stream
View Full AMGN Social Stream
Latest AMGN News From Around the Web
Below are the latest news stories about Amgen Inc that investors may wish to consider to help them evaluate AMGN as an investment opportunity.
Amgen has completed the acquisition of the clinical-stage biotechnology company Five Prime Therapeutics. Amgen had previously announced a tender offer to buy all outstanding common stock at the price of $38.00 per share in cash. The aggregate payment that was to be made for the merger is $1.9B, excluding transaction expenses. Amgen is a biotech company that focuses on unlocking biological potential and innovations that cater to patients suffering from serious illnesses. Amgen (AMGN) focuses on unmet needs in the human therapeutics field, and Five Prime Therapeutics (FPRX) will add to its overall oncology portfolio.
Amgen’s investigational treatment bemarituzumab has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration based on results from the Phase 2 FIGHT trial. The designation is for the treatment of gastric and gastroesophageal adenocarcinoma in combination with fluoropyrimidine, leucovorin, and oxaliplatin. Amgen (AMGN) Executive Vice president of Research and Development, David M. Reese, M.D., said, “The FIGHT trial is the first study to evaluate targeting the overexpression of FGFR2b in cancer. Bemarituzumab demonstrated clinically meaningful outcomes in key endpoints for patients with advanced gastric or gastroesophageal cancer as a frontline therapy.
The FDA has granted Breakthrough Therapy Designation to Amgen Inc's (NASDAQ: AMGN ) bemarituzumab for patients with gastric and gastroesophageal (GEJ) adenocarcinoma. The designation covers bemarituzumab as first-line treatment of fibroblast growth factor receptor 2b, overexpressing and human epidermal growth factor receptor 2-negative, metastatic and locally advanced … Full story available on Benzinga.com
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can-Fite Starts Preclinical Studies Required By FDA, EMA For Two Lead Drug Candidates Registration Filing
Can-Fite BioPharma (NYSE: CANF) has initiated a series of preclinical studies required by regulators to support potential marketing registration filings for its drug candidates Piclidenoson and Namodenoson in the U.S. and Europe. As part of marketing applications in the U.S. and Europe, both regulators require specific preclinical data to be submitted along with the pivotal Phase 3 data. Piclidenoson is now being evaluated in the COMFORT Phase 3 clinical study designed to establish Piclidenoson's superiority compared to placebo and non-inferiority compared to Amgen, Inc's (NASDAQ: AMGN) Otezla (Apremilast) for moderate-to-severe plaque psoriasis. A Phase 3 study of Namodenoson in the treatment of hepatocellular cancer (HCC) is expected to commence in the fourth quarter of this year. Pri...
AMGN Price Returns
|Ex-Dividend Date||Type||Payout Amount||Change|
|Loading, please wait...|
Continue Researching AMGNWant to see what other sources are saying about Amgen Inc's financials and stock price? Try the links below:
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!